CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 166.99% | -14.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 84.00% | 35.03% | |||
| Operating Income | -84.00% | -35.03% | |||
| Income Before Tax | -85.05% | -35.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -85.05% | -35.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.05% | -35.52% | |||
| EBIT | -84.00% | -35.03% | |||
| EBITDA | -84.00% | -35.06% | |||
| EPS Basic | -68.48% | 10.25% | |||
| Normalized Basic EPS | -68.48% | 10.25% | |||
| EPS Diluted | -68.45% | 10.28% | |||
| Normalized Diluted EPS | -68.48% | 10.25% | |||
| Average Basic Shares Outstanding | 9.82% | 51.01% | |||
| Average Diluted Shares Outstanding | 9.82% | 51.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||